Thrombolysis in acute stroke (I)

The Lancet

Volumn 385, Issue 9976, 2015, Pages 1394-

  Appelros, Peter ^a   Terént, Andreas ^b  

^a Örebro University   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL (TOPIC); FOLLOW UP; HUMAN; LETTER; META ANALYSIS (TOPIC); MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; STROKE PATIENT; SURVIVAL; FEMALE; MALE; STROKE;

FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84928701659     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60714-0     Document Type: Letter

References (4)

1. Emberson J., Lees KR, Lyden P, et al Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929-35.
2. Ward law J.M., Murray V, Berge E., del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2014; 7: 109-10.
3. The IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379: 2352-63.
4. Wardlaw JM, Murray V, Berge E., et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379: 2364-72.